Complications of intravenous immune globulin treatment in neurologic disease
Citation Manager Formats
Make Comment
See Comments

Abstract
Intravenous immune globulin (IVIg) is advocated as a safe treatment for immune-mediated neurologic disease. We reviewed the medical records of 88 patients who were given IVIg for a neurologic illness. Major complications in four patients (4.5%) included congestive heart failure in a patient with polymyositis, hypotension after a recent myocardial infarction, deep venous thrombosis in a bed-bound patient, and acute renal failure with diabetic nephropathy. Other adverse effects included vasomotor symptoms 26, headache 23, rash 5, leukopenia 4, fever 3, neutropenia 1, proteinuria (1.9 g/day) 1, viral syndrome 1, dyspnea 1, and pruritis 1. Fifty-two patients (59%) had some adverse effect of IVIg infusion, most commonly vasomotor symptoms, headaches, fever, or shortness of breath in 40 (45%), which improved with reduced infusion rate or symptomatic medications. Five (6%) had asymptomatic laboratory abnormalities and seven (8%) had other minor adverse effects. Adverse effects led to discontinuation of therapy in 16% and permanent termination of therapy in 10% of patients. There was no mortality or long-term morbidity. Although adverse effects were frequent, serious complications were rare except in patients with heart disease, renal insufficiency, and bed-bound state.
NEUROLOGY 1996;47: 674-677
Intravenous immune globulin (IVIg) has been advocated as a safe treatment for immune-mediated diseases and has gained wide use in neurologic practice. [1-3] Controlled studies have demonstrated benefit in dermatomyositis, [4] Guillian-Barre syndrome, [5] and chronic inflammatory demyelinating polyneuropathy (CIDP). [6] Benefit is reported for inclusion body myositis, [7] myasthenia gravis, [8] multiple sclerosis, [9] multifocal motor neuropathy with conduction block, [10] paraproteinemic neuropathy associated with antibodies to myelin-associated glycoprotein, [11] refractory polymyositis, [12] Lambert-Eaton syndrome, [13] stiff-man syndrome, [14] and Rasmussen's encephalitis. [15]
Reported complications include renal failure, [16-22] transmission of hepatitis C virus, [23,24] thromboembolism, [25,26] aseptic meningitis, [27-29] neutropenia, [30-32] coagulopathy, [33] rash, [34-37] anaphylaxis, [36] immune-complex arthritis, [38] and hemolysis. [39,40] Postulated risk factors include increased age, preexisting renal failure, diabetes, high infusion rate, [17] and high concentrations of sucrose as a stabilizing agent [3,20] for renal failure. Vascular disease, paraproteinemia, and other causes of increased serum viscosity are risks for thromboembolism. [25] Migraine increased the risk of aseptic meningitis [27] and IgA deficiency increased the risk of anaphylaxis. [36] Adverse effects are encountered in 1 to 15% of patients. [1,36,41,42] Because patients with neurologic diseases include many with possible risk factors, we reviewed the complications of IVIg therapy among patients with neurologic disease.
Methods.
We reviewed the medical records of all patients who received IVIg for a neurologic illness as inpatients or as outpatients in the hemotherapy laboratory from June 1992 to September 1994 at the Columbia-Presbyterian Medical Center. Cases were identified from pharmacy, outpatient hemotherapy laboratory, and neurology admission records. We excluded 12 patients who received only the first infusion under observation in the outpatient unit and the remainder with home therapy.
Results.
Eighty-eight patients received one to 18 courses of IVIg for a total of 650 infusions. Ages ranged from 16 to 81 years. A total of 413 infusions were given on an inpatient basis and 237 as outpatient. The total dose was generally 2 g/kg given in 2 to 5 days, but the daily dose ranged from 20 to 100 g given for 1 to 9 days.
Diagnostic indications included CIDP 25, myasthenia gravis 14, Guillain-Barre syndrome 10, inclusion body myositis 6, inflammatory diabetic neuropathy 6, ALS 5, neuropathy associated with monoclonal gammopathy 4, other neuropathy 4, polymyositis 4, brachial plexitis 2, multifocal motor neuropathy with conduction block 2, dermatomyositis 1, HTLV-1 myelopathy 1, cytomegalovirus polyradiculitis 1, multiple sclerosis 1, CNS vasculitis 1, and presumed paraneoplastic encephalomyelitis 1.
Seventeen patients (19%) had diabetes mellitus and were treated for inflammatory diabetic neuropathy, inclusion body myositis, brachial neuritis, polymyositis, Guillain-Barre syndrome, CIDP, or myasthenia gravis.
Major complications included the following: congestive heart failure, deep venous thrombosis, acute hypotension, and acute oliguric renal failure.
Congestive heart failure occurred in a patient with polymyositis with secondary cardiomyopathy and paroxysmal atrial fibrillation. She was to receive 50 g of IVIg in 10.5 hours for each of 2 days, a dose she had tolerated in three earlier courses. However, midway through the second day she developed dyspnea and orthopnea. The infusion was discontinued and furosemide was given intravenously, with prompt improvement.
Deep venous thrombosis was diagnosed in a patient with CIDP who was bed-bound; the left leg became edematous while she was receiving IVIg.
A severe hypotensive episode occurred during the first infusion of IVIg in a patient with a recent myocardial infarction. Intravenous vasopressor therapy was given to support blood pressure for 1 day. The patient tolerated further courses of IVIg without problem.
Acute oliguric renal failure developed in a 62-year-old woman with diabetic inflammatory neuropathy and mild diabetic nephropathy (blood urea nitrogen [BUN] 39 mg/dl, creatinine (Cr) 1.9 mg/dl before IVIg, proteinuria 761 mg/24 hr 18 months previously). After two consecutive days of IVIg (60 g at 5 g/hour), the BUN rose to 62 mg/dl and Cr to 6.5 mg/dl. Quantitative urinary protein was 21 g in 24 hours. One hemodialysis treatment was given and renal function rapidly improved, with a new baseline Cr of 2 to 3 mg/dl within 1 week.
Other adverse effects included vasomotor symptoms (defined below): 26 (30%), headache: 23 (26%), leukopenia: 4 (WBC < 4), rash: 5 (6%), fever: 3 (3%), neutropenia: 1, proteinuria: 1, pruritus: 1, dyspnea: 1, viral syndrome (sore throat, myalgias, adenopathy, fever, and elevated transaminases): 1.
Vasomotor symptoms were broadly defined as any combination of chills, nausea, skin flushing, chest tightness, or wheezing. [43] All of these symptoms were seen 10 minutes into the first dose of IVIg in one woman with multifocal motor neuropathy with conduction block; the syndrome was attributed to anaphylaxis and resolved within minutes after the infusion was stopped and diphenhydramine was given intravenously. Her vital signs were stable throughout the episode. Of the 26 patients with vasomotor symptoms, chills occurred in 14 patients, nausea in 12, arthralgias in 5, chest tightness in 5, vomiting in 5, facial flushing in 4, myalgias in 4, fatigue in 3, and dizziness in 2.
Neutropenia was seen in one patient. After two days of IVIg, the WBC dropped from 4.2 to 1.9 (103/mm3). After four doses the WBC was 1.7 and the absolute neutrophil count was 306/mm3. The neutrophil count began to recover the day after the last IVIg infusion and then returned to normal.
Leukopenia developed in four patients. Rash occurred in five (6%) patients. Proteinuria occurred in an 18-year-old woman with Guillain-Barre syndrome who received 15 g of IVIg at 5 g/hour before she developed a maculopapular rash. She had no previous renal disease; urine analysis and BUN/Cr were normal on the morning of treatment. On the day after treatment, proteinuria was noted and quantified at 1.9 g/24hr, which disappeared within 1 week.
Fifty-two (59%) of our patients had some adverse effect of IVIg therapy. Besides the four with major complications, these included 40 (45%) with vasomotor symptoms, shortness of breath, headache, or fever that could be reduced with slowing the rate of infusion or using symptomatic medications. Five (6%) had laboratory abnormalities including neutropenia, leukopenia, or proteinuria and seven (8%) had other adverse effects including rash, pruritus, or viral-like syndrome. Of patients with diabetes mellitus, nine of 17 (53%) had some adverse effect of IVIg therapy.
Treatment was terminated in nine (10%) patients, because of vasomotor symptoms in two patients, headache four, heart failure one, renal failure one, rash 1. Treatment was temporarily interrupted in five (6%) patients, because of vasomotor symptoms in three patients, headache one, hypotension 1.
Discussion.
Our frequency of side effects (59%) is higher than the often cited 1 to 15%. [1] However, our frequency of side effects was similar to that of Bertorini et al., [44] who found an 81% frequency of complications in 42 patients with neuromuscular disease. Sekul et al. [27] reported headaches in 56% of their patients compared with our 26%. In earlier series, the patients may have been younger, without accompanying diabetes mellitus, heart disease, vascular disease, and renal insufficiency. Also doses were often lower [41,42] than the customary 2.0 g/kg for immune-mediated diseases.
The use of IVIg was associated with frequent adverse effects, but serious adverse reactions occurred in only four (4.5%) of our patients and included hypotension, congestive heart failure, renal failure, and deep venous thrombosis. All patients had an identifiable risk factor: preexisting heart disease, diabetic nephropathy, or confinement to bed. All patients who developed acute renal failure, including ours, had mild preexisting renal insufficiency. [16-22] However, one of our patients, age 19, and with no prior renal disease, developed reversible proteinuria of 1.9 g/24 hours after a small dose of IVIg at a slow rate for only 1 day. Therefore it is not always possible to predict renal complications. This patient had Guillain-Barre syndrome, which may be associated with membranous glomerulonephritis that could explain the proteinuria, [45,46] but the temporal correlation with IVIg and the quick resolution made that explanation unlikely.
Previous reports of acute renal failure occurred in patients given Sandoglobulin, [16-20] which contains sucrose as a stabilizing agent. Renal biopsies showed swelling and vacuolization of the proximal tubular epithelial cytoplasm typical of damage from a highsolute load, attributed to sucrose. [20] In our case of renal failure, the patient received Gammar (Armour), which also contains sucrose.
Both patients with cardiac complications had preexisting cardiac disease. The exacerbation of heart failure was likely due to the volume overload from IVIg.
Most adverse effects included vasomotor symptoms or headache that was usually controlled by reducing the flow rate or using symptomatic medications, even though these effects sometimes led to discontinuation of therapy. Acetaminophen and diphenhydramine were effective. Most headaches were mild but seven patients had severe headache and four patients with severe headache later received prophalactic steroids (100 to 200 mg hydrocortisone intravenously or 100 mg prednisone orally) as premedication, [47] which was effective. In five patients therapy stopped because of headache. In the series of Sekul et al., [27] 50% of patients with migraine had aseptic meningitis with IVIg therapy. Similarly, three of seven (43%) of our patients with migraine developed headaches during an infusion, compared with 25% of those without migraine. We did not identify aseptic meningitis, in contrast to a frequency of 11% in the series of Sekul et al. [27] We may have missed some cases by not performing lumbar puncture in all patients with headache. However, none of our patients had nuchal rigidity, drowsiness or lethargy, fever, photophobia, or painful eye movements. [27]
One patient developed a reversible neutropenia during his second exposure to IVIg. Neutropenia is a rare complication of IVIg. [30-32] During his third course 3 months later, he again developed neutropenia. Other patients have had recurrent episodes of neutropenia, which may be secondary to serum factors in individual patients in concert with the globulin preparation. [31] The recurrent episodes in our patient support this theory. During his first course of IVIg, he had a reactive leukocytosis while being treated for osteomyelitis and after receiving IVIg his WBC dropped by more than 50% to 3.9 103/mm3. Though not defined as a complication, we noted a drop of 50% or more in the peripheral WBC in 12 of 41 patients (29%), with cell counts available within 1 week before and within 2 weeks after the first infusion. Koffman and Dalakas [48] reported a 33% drop in the lymphocyte count in 44 of 46 patients. We did not have differential counts on all patients to determine which white cell types were affected. Only four of our patients became leukopenic, always transient and asymptomatic. In one reported patient mouth ulcers developed during neutropenic episodes. [32]
There are previous reports of eczema, [34] erythema multiforme, [36,37] purpuric erythema, [37] and alopecia. [35] Rash occurred in five (6%) of our patients: (1) An urticarial eruption on the arms recurred in other courses of IVIg and was controlled with diphenhydramine. (2) A maculopapular rash on the trunk and proximal limbs arose during the first dose of IVIg, and treatment was terminated. (3) A nonpruritic petechial rash with a normal platelet count occurred on the fifth infusion day and began to resolve the next day. (4) Biopsy-proven eczematous dermatitis arose on the palmar surface of the hands during the second course of IVIg; it did not recur with future courses. (5) A rash developed after the fifth and last treatment, involving the face and hands.
There were no cases of anaphylaxis. Only one of our patients had IgA deficiency and she had no adverse reaction.
We identified no cases of hepatitis B or C transmission, a reported risk in particular IVIg preparations. [23,24] Most available preparations are now treated to prevent hepatitis B and C viral transmission. [24,49,50]
Headache and vasomotor symptoms, usually considered minor adverse effects, led to interruption in therapy of 10 patients and permanent discontinuation in six (7%). Sixteen percent of all patients had therapy interrupted either temporarily or permanently because of adverse effects.
There was no mortality or long-term morbidity in our series, but one patient (with renal failure) required dialysis and another was given warfarin for venous thrombosis. Potentially serious complications, as with all forms of immunosuppressive therapy, must be recognized and anticipated.
- Copyright 1996 by Advanstar Communications Inc.
REFERENCES
- 1.↵
National Institute of Health Consensus Conference: Intravenous immune globulin prevention and treatment of disease. JAMA 1990;264:3189-3193.
- 2.
- 3.↵
Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Arch Neurol 1993;50:135-136.
- 4.↵
- 5.↵
- 6.↵
Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
- 7.↵
Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-879.
- 8.↵
Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High dose IVIg in the management of MG. Arch Intern Med 1986;146:1365-1368.
- 9.↵
Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of IVIg in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:1233-1236.
- 10.↵
Chaudhrey V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-242.
- 11.↵
Cook D, Dalakas MC, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40:212-214.
- 12.↵
- 13.↵
- 14.↵
- 15.↵
- 16.↵
- 17.↵
- 18.
Phillips AO. Renal failure and intravenous immunoglobulin [letter]. Clin Nephrol 1992;37:217.
- 19.
Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83-86.
- 20.↵
Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139.
- 21.
- 22.
Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin [letter]. Clin Nephrol 1992;37:216-217.
- 23.↵
- 24.↵
- 25.↵
Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226.
- 26.
Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-258.
- 27.↵
Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994;121:259-262.
- 28.
- 29.
Casteels-van Daele M, Wijndaele L, Brock P, Kruger M, Gillis P. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry 1992;55:980-981.
- 30.↵
Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin [letter]. N Engl J Med 1991;326:270-271.
- 31.↵
Bower LR, Brey RL, Rogers SJ, Stroncek DF, Jackson CE. Intravenous immunoglobulin-induced neutropenia [abstract]. Ann Neurol 1994;36:291.
- 32.↵
Majer RV, Green PJ. Neutropenia caused by intravenous immunoglobulin [letter]. BMJ 1988;296:1262.
- 33.↵
- 34.↵
Barucha C, McMillan JC. Eczema after intravenous infusion of immunoglobulin [letter]. BMJ 1987;295:1141.
- 35.↵
Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion [letter]. Lancet 1987;i:1436.
- 36.↵
Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-262.
- 37.↵
Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica (Suppl) 1993;78:35-40.
- 38.↵
Lisak RP. Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996;135:85-88.
- 39.↵
- 40.
Nicholls MD, Cummins JC, Davies VJ, Greenwood JK. Haemolysis induced by intravenously administered immunoglobulin. Med J Aust 1989;150:404-406.
- 41.↵
Cooperative Group for the Study of Immunoglobulin in chronic lymphocytic leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 1988;319:902-907.
- 42.
National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Eng J Med 1991;325:73-80.
- 43.↵
Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-292.
- 44.↵
- 45.↵
- 46.
Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barre syndrome. Philadelphia: F.A. Davis, 1991.
- 47.↵
Lederman HM, Roifman CM, Lavi S, Gelfand EW. Corticosteriods for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med 1986;81:443-446.
- 48.↵
Koffman B, Dalakas MC. Effect of high-dose intravenous immunoglobulin (IVIg) on hematological and serum chemistry profiles in the treatment of patients with neuromuscular diseases [abstract]. Neurology 1995;45(suppl 4):A235.
- 49.
Horowitz B, Prince AM, Horowitz MS, Watklevicz C. Viral safety of solvent-detergent treated blood products. In: Brown F, ed: Virological safety aspects of plasma derivatives. Dev Biol Stand. Basel: Karger, 1993;81:147-161.
- 50.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Drugs and Devices
Intravenous immunoglobulin for treatment of neuromuscular diseaseKatherine Ruzhansky, Thomas H. Brannagan III et al.Neurology: Clinical Practice, October 04, 2013 -
Article
Thromboembolic risk with IVIgIncidence and risk factors in patients with inflammatory neuropathyMahima Kapoor, Jennifer Spillane, Christina Englezou et al.Neurology, December 18, 2019 -
Articles
Activity-dependent conduction block in multifocal motor neuropathyMagnetic fatigue testH. Nodera, H. Bostock, Y. Izumi et al.Neurology, July 24, 2006 -
Brief Communications
Rapid infusion of intravenous immune globulin in patients with neuromuscular disordersJ. A. Grillo, K. C. Gorson, A. H. Ropper et al.Neurology, November 13, 2001